For instance, the results of the KAMILLA trial, which investigated the efficacy of T-DM1 in treating HER2-positive breast cancer with brain metastases, showed that mPFS, mOS, and ORR were 5.5 (95% CI [5.3, 5.6]) months, 18.9 (95% CI [17.1, 21.3]) months, and 21.4% (95% CI [14.6, 29.6]), respectively (Montemurro et al., 2020). The gene discussed is ERBB2; the disease is breast carcinoma.